Friday, April 29, 2011

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) plunged 21% in friday's trading session after analyst's downgrade

Shares of Regeneron plunged 20% after analysts at RBC Capital cut their rating on the stock to sector perform from outperform. Read previous story .
If we see the company's performance and development pipeline, this dip might be utilized as a buying opportunity.


Post a Comment